Trial Profile
Evaluate Persistence of Immune Response of GSK Biologicals' TWINRIX Vaccine Administered According to 0,6 Month Schedule Versus TWINRIX JUNIOR Administered According to 0,1,6 Month Schedule, in Subjects Aged 12-15 Years at Time of First Vaccine Dose.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Hepatitis A-hepatitis B vaccine (Primary)
- Indications Hepatitis A; Hepatitis B
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GSK
- 27 Oct 2008 Actual end date changed Jul 2008 to Jun 2004 as reported by ClinicalTrials.gov.
- 09 Sep 2008 Additional trial identifiers 100566,100567,100568,100569,100570 added as reported by ClinicalTrials.gov.
- 09 Sep 2008 Primary endpoint identified as antibody level as reported by ClinicalTrials.gov